statistics data analysis version 14 1 (STATA Corporation)
STATA Corporation is a verified supplier 
99
Structured Review
STATA Corporation
statistics data analysis version 14 1
Statistics Data Analysis Version 14 1, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 49426 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+14+data+analysis/STATA+14%2E0/pm41819638-92-29-28
Average 99 stars, based on 49426 article reviews
Statistics Data Analysis Version 14 1, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 49426 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+14+data+analysis/STATA+14%2E0/pm41819638-92-29-28
Average 99 stars, based on 49426 article reviews
statistics data analysis version 14 1 - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Software:Article Title: Evaluating the Effect of Concomitant Azoles on Anticoagulant Prescribing Practices in Transplant Patients: A National Survey of Clinicians Article Snippet: .. Statistical analysis was completed using STATA Article Title: Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers Article Snippet: Objective: The objective of this study was to assess the effectiveness of human epididymis protein 4 (HE4) and cancer antigen 125 (CA125), and risk of ovarian malignancy algorithm (ROMA) in identifying type I and type II epithelial ovarian cancers (EOCs).. Methods: A cross-sectional diagnostic study was conducted of 499 Thai women older than 18 years who had clinically diagnosed pelvic masses and underwent elective surgery at our hospital between July 2012 and July 2014.. Preoperative serum HE4 and CA125 levels were measured, and postoperative pathologic slides were reviewed. Article Title: Obesity impacts acute rejection but not allograft function improvement in the setting of belatacept conversion. Article Snippet: Belatacept is an alternative to calcineurin inhibitor (CNI) immunosuppression in renal transplant (RT) recipients both in the de novo and conversion settings13 As there is increasing use of this medication, different patient factors should be considered, including body habitus.. Pharmacokinetic (PK) data demonstrate elevated clearance and volume of central and peripheral compartments with increasing body weight4 However, there are limited data of belatacept use in obese patients (body mass index [BMI] >35 kg/m2).. The purpose of this study was to compare acute rejection, allograft function, and safety outcomes of obese versus nonobese RT recipients converted to belatacept. Article Title: Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection Article Snippet: Transplantation ■ November 2020 ■ Volume 104 ■ Number 11 www.transplantjournal.com 2403 Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection Alicia B. Lichvar, PharmD, MS, Simon Tremblay, PharmD, PhD, Abbie D. Leino, PharmD, MS, Adele R. Shields, PharmD, Michael A. Cardi, MD, Bassam G. Abu Jawdeh, MD, Amit Govil, MD, Joseph Kremer, MD, Madison Cuffy, MD, MBA, Flavio Paterno, MD, Tayyab Diwan, MD, Paul Brailey, BS, Alin Girnita, MD, PhD, Rita R. Alloway, PharmD, and E. Steve Woodle, MD Generated:Article Title: Obesity impacts acute rejection but not allograft function improvement in the setting of belatacept conversion. Article Snippet: Belatacept is an alternative to calcineurin inhibitor (CNI) immunosuppression in renal transplant (RT) recipients both in the de novo and conversion settings13 As there is increasing use of this medication, different patient factors should be considered, including body habitus.. Pharmacokinetic (PK) data demonstrate elevated clearance and volume of central and peripheral compartments with increasing body weight4 However, there are limited data of belatacept use in obese patients (body mass index [BMI] >35 kg/m2).. The purpose of this study was to compare acute rejection, allograft function, and safety outcomes of obese versus nonobese RT recipients converted to belatacept. Article Title: Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection Article Snippet: Transplantation ■ November 2020 ■ Volume 104 ■ Number 11 www.transplantjournal.com 2403 Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection Alicia B. Lichvar, PharmD, MS, Simon Tremblay, PharmD, PhD, Abbie D. Leino, PharmD, MS, Adele R. Shields, PharmD, Michael A. Cardi, MD, Bassam G. Abu Jawdeh, MD, Amit Govil, MD, Joseph Kremer, MD, Madison Cuffy, MD, MBA, Flavio Paterno, MD, Tayyab Diwan, MD, Paul Brailey, BS, Alin Girnita, MD, PhD, Rita R. Alloway, PharmD, and E. Steve Woodle, MD |